• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Will unpredictable side effects dim the promise of new Alzheimer ’s drugs?
A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months. As many neurologists, patients, and brain scientists celebrate, they’re also nervously eyeing complications from treatment: brain swelling and bleeding, which in clinical trials affected up to about one-third of patients and ranged from asymptomatic to fatal. The side effect—amyloid-related imaging abnormalities, or ARIA—remains mysterious. “We don’...
Source: Science of Aging Knowledge Environment - August 2, 2023 Category: Geriatrics Source Type: research

Why is Clinical fMRI in a Resting State?
Conclusions Despite some perceived impediments to expanding clinical rs-fMRI use, neuroradiologists were generally enthusiastic about rs-fMRI in research and clinical applications, believing that their current workplace MRI systems are suitable for rs-fMRI acquisition. Many of the concerns associated with using rs-fMRI in clinical contexts are related to: (1) developing better methods for minimizing physiological noise effects, (2) improving methods for detecting the spatial characteristics of clinically-relevant brain processing systems in individual patients, and (3) overcoming remaining standardization, training, and r...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Can you guess what might be the third-leading cause of death?
A study by patient safety researchers has found that "medical errors" in hospitals and other facilities now may be the third-leading cause of death in the United States, The Washington Post reports. At 251,000 American lives every year, that tops respiratory disease, accidents, stroke and Alzheimer's, the researchers report in BMJ. Martin Makary, a Johns Hopkins University professor, led the research and said it ranges from bad doctors to botched communication when patients get handed off from…
Source: bizjournals.com Health Care:Biotechnology headlines - May 4, 2016 Category: Biotechnology Source Type: news

Selected Health and Life Style Factors and Time to Phenoconversion in Huntington's Disease (S47.003)
CONCLUSIONS: An association between total lifetime caffeinated soda consumption and earlier HD onset was observed, but this was not seen with other caffeinated beverages and may be spurious. Other life style risk factors associated with PD or AD did not modify time to phenoconversion in HD.SUPPORT: NIH (# 2 R01 HG002449-06), National Human Genome Research Institute, National Institute of Neurological Disorders and StrokeDisclosure: Dr. Tanner has received personal compensation for activities with AbbVie and Adamas Pharmaceuticals as a scientific advisor. Dr. Marder has received personal compensation in an editorial capacit...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Tanner, C., Marder, K., Eberly, S., Biglan, K., Oakes, D., Shoulson, I. Tags: Movement Disorders: Huntington ' s Disease, Ataxia, and Wilson Source Type: research